How Analysts Rated GlaxoSmithKline plc (NYSE:GSK) Last Week?

May 16, 2018 - By Robin Claypool

GlaxoSmithKline plc (NYSE:GSK) Logo

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Among 5 analysts covering GlaxoSmithKline (NYSE:GSK), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. GlaxoSmithKline had 6 analyst reports since November 27, 2017 according to SRatingsIntel. The rating was upgraded by UBS on Monday, November 27 to “Buy”. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Hold” rating given on Monday, December 11 by Cowen & Co. BNP Paribas upgraded the stock to “Buy” rating in Wednesday, April 4 report. The firm earned “Buy” rating on Tuesday, January 16 by Barclays Capital. Cowen & Co maintained GlaxoSmithKline plc (NYSE:GSK) on Wednesday, February 14 with “Hold” rating. Below is a list of GlaxoSmithKline plc (NYSE:GSK) latest ratings and price target changes.

04/04/2018 Broker: BNP Paribas Rating: Buy Upgrade
14/02/2018 Broker: Cowen & Co Rating: Hold New Target: $40.0 Maintain
16/01/2018 Broker: Barclays Capital Rating: Buy Upgrade
11/12/2017 Broker: Cowen & Co Rating: Hold New Target: $38.0 Maintain
30/11/2017 Broker: Argus Research Rating: Buy New Target: $40.0
27/11/2017 Broker: UBS Rating: Buy Upgrade

The stock increased 0.40% or $0.1601 during the last trading session, reaching $39.8901. About 595,437 shares traded. GlaxoSmithKline plc (NYSE:GSK) has declined 10.07% since May 16, 2017 and is downtrending. It has underperformed by 21.62% the S&P500.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of $97.32 billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 45.64 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: which released: “GlaxoSmithKline Plc (GSK) Q1 2018 Results – Earnings Call Transcript” on April 25, 2018, also with their article: “Exelixis: Time To Excel” published on May 14, 2018, published: “GlaxoSmithKline Q1 2018: Still Too Many Uncertainties” on April 29, 2018. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: and their article: “FDA OKs expanded use for Glaxo’s Trelegy Ellipta” published on April 24, 2018 as well as‘s news article titled: “Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)” with publication date: April 20, 2018.

GlaxoSmithKline plc (NYSE:GSK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: